Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PYXS · as of Sep 30, 2025
Ownership Breakdown
74
Institutional Holders
▼ 1 vs Q2
$59.74M
Total Inst. Value
▲ $29.54M vs Q2
63.36M
Shares Outstanding
freeFloat 63.79%
26.83M
13F Shares Held
▼ 661,769 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PYXS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
PFIZER INC pharmaceutical preparations | 7.03M | 11.36% | 11.36% | $15.61B | Nov 13, 2025 | — held |
LAURION CAPITAL MANAGEMENT LP pharmaceutical preparations | 3.63M | 5.86% | 5.86% | $8.05B | Nov 17, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.50M | 4.04% | 4.04% | $5.55B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 2.16M | 3.49% | 3.49% | $4.80B | Nov 7, 2025 | ▲ 14.6K |
PERCEPTIVE ADVISORS LLC pharmaceutical preparations | 1.18M | 1.90% | 1.90% | $2.62B | Nov 14, 2025 | NEW |
PALO ALTO INVESTORS LP pharmaceutical preparations | 1.04M | 1.68% | 1.68% | $2.30B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 815.3K | 1.32% | 1.32% | $1.81B | Nov 14, 2025 | ▼ 2.72M |
STEMPOINT CAPITAL LP pharmaceutical preparations | 689.5K | 1.11% | 1.11% | $1.53B | Nov 14, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 683.7K | 1.10% | 1.10% | $1.52B | Nov 12, 2025 | ▼ 243.1K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 615.9K | 99.47% | 99.47% | $1.37B | Feb 3, 2026 | ▲ 593.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
8
Increased
+878.8K shares14
New Positions
first time holders16
Decreased
−3.66M shares0
Sold Out
fully exitedNet shares change (top 50)
2.78M
+878.8K / −3.66M
Net new holders
+6
14 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PYXS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Dupont Jakob director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
Wadhane Jitendra Prin Fin & Acct Officer | Mar 24, 2026 | Award | 109,461 | — | — | 512.9K | Form 4 ↗ |
Wadhane Jitendra Prin Fin & Acct Officer | Mar 24, 2026 | Award | 262,635 | $1.36 | $357.2K | 262.6K | Form 4 ↗ |
FLAVIN JOHN L director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
Metzger Michael A director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
Lewis-Hall Freda C director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
Cline Darren S director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
HUMPHREY RACHEL director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
Palani Santhosh director | Mar 24, 2026 | Award | 45,867 | $1.36 | $62.4K | 45.9K | Form 4 ↗ |
HUMPHREY RACHEL director | Apr 14, 2025 | Sale | 1,400 | $0.97 | $1.4K | 95.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Pyxis Oncology, Inc. (PYXS) is primarily owned by institutional investors, who hold approximately 42.4% of total shares outstanding. Company insiders own approximately 36.21%, while retail and public investors account for the remaining 21.44%.
The largest institutional shareholder of Pyxis Oncology, Inc. is PFIZER INC, holding approximately 7.03 million shares — equal to 11.36% of outstanding shares — as of September 30, 2025.
A total of 74 institutional investors currently hold PYXS stock, with a combined institutional value of approximately $59,741,454 as of the most recent 13F filing period.
Frequently asked questions
PYXS ownershipPyxis Oncology, Inc. (PYXS) is primarily owned by institutional investors, who hold approximately 42.4% of shares. The largest shareholder is PFIZER INC with a 11.36% stake. Company insiders hold 36.21%. Data sourced from SEC Form 13F as of September 30, 2025.